Neutralization Testing-based Immunogenicity Analysis of Recent Prevalent Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Sublineages

Ann Lab Med. 2024 May 1;44(3):289-293. doi: 10.3343/alm.2023.0256. Epub 2023 Dec 13.

Abstract

Although WHO declared the end of the public health emergency for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), XBB lineages continue to evolve and emerge globally. In particular, XBB.1.5 and XBB.1.16 are raising concerns because of their high immune evasion, leading to apprehensions regarding vaccine efficacy reduction and potential reinfection. We aimed to investigate the COVID-19 outbreak in Korea and predict the likelihood of reinfection by testing neutralizing activity against live viruses from the S clade and 19 Omicron sublineages. We found a significant risk of infection with the currently prevalent XBB lineage for individuals who were either vaccinated early or infected during the initial Omicron outbreak. Vaccinated individuals were better equipped than unvaccinated individuals to produce neutralizing antibodies for other SARS-CoV-2 variants upon infection. Therefore, unvaccinated individuals do not easily develop neutralizing activity against other variants and face the highest risk of reinfection by the XBB lineage. Our study provides important information to facilitate the development of strategies for monitoring populations that would be the most susceptible to new COVID-19 outbreaks.

Keywords: Disease outbreaks; Neutralization antibodies; Omicron; Reinfection; SARS-CoV-2.

MeSH terms

  • Antibodies, Viral
  • COVID-19*
  • Disease Outbreaks
  • Humans
  • Reinfection
  • SARS-CoV-2*

Substances

  • Antibodies, Viral

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

RESEARCH FUNDING This study was supported by a grant from the KDCA (grant No. 6300-6331-301).